Physician profile

Robert J Samuelson

Pulmonary Disease · New York, NY

NPI 1497843858

$1,952.50

in general payments reported to CMS, 2019-2025

27 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $590.88 2019
Glaxosmithkline, LLC. $351.22 2019
Insmed, INC. $149.20 2019
Pfizer INC. $129.67 2019
Takeda Pharmaceuticals U.S.A., INC. $88.21 2019
Amgen INC. $85.68 2019
Amarin Pharma, INC. $70.45 2019
Janssen Pharmaceuticals, INC $65.44 2019
Sanofi Pasteur INC. $37.48 2019
Boston Scientific Corporation $35.11 2019
Advanced Respiratory, INC $30.62 2019
Allergan, INC. $30.17 2019
Gilead Sciences, INC. $25.00 2019
Grifols USA, LLC $24.90 2019
Novartis Pharmaceuticals Corporation $24.81 2019
Show all 27 companies
CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $24.63 2019
Dynavax Technologies Corporation $23.24 2019
Melinta Therapeutics, LLC $21.82 2019
Kowa Pharmaceuticals America, INC. $21.25 2019
Janssen Biotech, INC. $19.65 2019
Electromed, INC. $19.00 2019
Philips North America LLC $18.35 2019
Shire North American Group INC $16.88 2019
Lilly USA, LLC $13.57 2019
Merck Sharp & Dohme LLC $12.20 2019
Arbor Pharmaceuticals, INC. $11.75 2019
E.R. Squibb & Sons, L.L.C. $11.32 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert J Samuelson

$1,952.50

in general payments reported 2019-2025

Years
2019
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/67135/robert-j-samuelson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.